˫ä·¨double-blind technique ÌìȻҩÎïcrude drugs; natural drugs Ó²¸à¼Áplaster ÓÐЧ°ëË¥ÆÚeffective halt
ÓÐЧÂÊeffective rate ÓÐЧŨ¶Èeffective concentration
ÖÎÁÆÁ¿therapeutic dose ÖÎÁÆÒ©ÎïÁÙ²âtherapeutic drug monitoring; TDM
ÖÎÁÆÖ¸Êýtherapeutic index TI ÖÎÁÆ×÷ÓÃtherapeutic action
ÓÒÐýÌÇdextrose ÓÒÐýÌådextrorotatory form
ãмÁÁ¿threshold dose ÔØÌåcarrier
ÊÜÌ弤¶¯¼Áreceptor stimulant ÊÜÌåÞ׿¹¼Áreceptor antagonist
Íâ¶¾ËØexotoxin ÍâÏûÐýÌåraceme
Ò©Îï·ÖÎöpharmaceutical analysis Ò©Îﻯѧpharmaceutical chemistry Ò©Æ·¸ºÔðÆÚallotted date of drug quality ensuring by manufacturer
Ò©Æ·¹ÜÀí·¨drug administration law Ò©Æ·ÅúºÅdrug batch number
ҩƷʹÓÃÆÚlimit date of using a drug after its production
Ò©Æ·ÓÐЧÆÚexpiry date; date of expiration Ò©Æ·ÖÊÁ¿±ê×¼drug standard ·¢½Ífermentation ·¨¶¨´¦·½official formula
ж¨´¦·½cipher prescription Ðò¹áÉè¼Æsequential design
¶àÌÇpolyose ¶àëÄpolypeptide
µç½âelectrolyzation µç½âÖÊelectrolyte
¼¤»î¼Áactivator ¼¤»î×÷ÓÃactivation
¼¤ËØhormone ¼¤ËØÔprohormone
ÖмäÌåintermediate ÖúÂ˼Áfilter aid
ÖúÈܼÁcomplex solubilizer ÖúÐü¼Ásuspending agent
×ÔÉíÃâÒßautoimmunity ×é°·histamine
×î´óÄÍÊܼÁÁ¿maximal tolerable dose; LDO ×î´óÎÞ×÷ÓüÁÁ¿maxial noneffective dose; EDO
×îСÏÔÖø²îÊýleast significant difference×ô¼Áadjuvant
×óÐýÌÇlevulose ×óÐýÌålevorotatory form
6-Á×ËáÆÏÌÑÌÇÍÑÇâøglucose-6-phosphate dehydrogenase²»ÍêÈ«¿¹Ôincomplete antigen
Janbon×ÛºÏÖ¢Janbon's syndrome PPBŨ¶Èparts per billion concentration

